Inactief instrument

Andere talen Auris Medical Holding Ltd Nasdaq

Aandelen

BMG070251027

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation	01/05
Altamira Therapeutics Ltd. Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation	01/05
Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal	24/04
Altamira Therapeutics Ltd. Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal	24/04
Altamira Therapeutics : Notice of the Annual General Meeting of Shareholders of Altamira Therapeutics Ltd. (the “Company”) to be held on May 16, 2024 - Form 6-K	16/04
Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results	10/04
Altamira Therapeutics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	10/04
Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024	04/04
Sector Update: Health Care Stocks Decline Late Afternoon	25/03
Top Midday Gainers	25/03
Sector Update: Health Care Stocks Softer in Afternoon Trading	25/03
Altamira, Univercells Partner to Test mRNA Vaccine Delivery; Shares Surge	25/03
Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines	25/03
Altamira Therapeutics Ltd. Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines	25/03
Altamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal	07/02
Altamira Therapeutics? Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal	07/02
Altamira Files Second Provisional Patent Application in Cancer Treatment; Shares Rise	24/01
Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment	24/01
Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment	24/01
Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit	08/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Auris Medical Holding Ltd Nasdaq

Aandelen

BMG070251027

Andere talen

Filters